Telegraph Hill Partners — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Mosaic Biosciences is an integrated biologics discovery partner offering antibody discovery, protein engineering, and translational pharmacology services to advance complex antibody and protein therapeutics from concept to candidate selection.
BiotechDeep TechBoulder, US
Eric Furfine(Chief Scientific Officer)Alexei Kazantsev(Vice President Protein Design and Engineering)Tracey Mullen(Chief Strategy Officer)Scott Glaser(SVP, Biologics Discovery)Dan Mitchell(Director)Martin Stanton(Executive Officer, Director)
Board seatJeanette WelshRob Capone· per SEC Form D
Panome Bio provides multi-omics discovery services using mass spectrometry-based metabolomics and proteomics to identify biomarkers and generate mechanistic insights for research institutions and pharmaceutical companies.
AI & Machine LearningBiotechDeep TechSaint Louis, US
Alexander Herzick(Director)Edward Weinstein(Executive Officer, Director)Tom Cohen(Executive Officer)
BoardDavid Smoller(Director)
Board seatDeval LashkariRob Capone· per SEC Form D
RevMedica develops smart surgical stapling and soft tissue management systems for minimally invasive and robotic procedures, designed to provide real-time intraoperative data and improve clinical decision-making for surgeons.
AI & Machine LearningHealthtechMedical DevicesMiddletown, US
Thomas Wenchell(Chief Executive Officer and Co-Founder)inC. Robert Satti(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.